A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment (LUMIOS)

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Safety and Tolerability of Cenerimod in Adult Patients With Systemic Lupus Erythematosus and Active Lupus Nephritis in Combination With Background Therapy

The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are:

• Does cenerimod improve kidney function in participants?
• What medical problems do participants have when taking cenerimod?

Researchers will compare cenerimod to a placebo (a look-alike substance that contains no drug) to see how well cenerimod works when it is added to regular treatment.

Participants will:

• Take cenerimod or a placebo every day for 76 weeks (approximately 1.5 years), on top of regular treatment.
• Visit the clinic every 1 to 3 months for checkups and tests.

Study Overview

• Status: Recruiting
• Conditions: Lupus Erythematosus, Systemic; Nephritis, Lupus
• Intervention / Treatment: Drug: Cenerimod; Drug: Placebo

• Study Type: Interventional
• Enrollment (Estimated): 300
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Viatris Innovation Clinical Trial Information; Phone Number: +1 908 435 2675; Email: viatrisinnovationclinicaltrials@viatris.com

Study Locations

• United States
  • Florida
    • Kissimmee, Florida, United States, 34741
      • Recruiting
      • Alloy Clinical Research LLC
    • Miami, Florida, United States, 33136
      • Recruiting
      • SouthCoast Research Center
    • Miami, Florida, United States, 33155
      • Recruiting
      • Allied Biomedical Research Institute
    • Miami, Florida, United States, 33172
      • Recruiting
      • ProfessionalResearchCenter INC
    • Miami, Florida, United States, 33155
      • Recruiting
      • DH NationalResearchCenters INC
    • Miami Lakes, Florida, United States, 33014
      • Recruiting
      • San Marcus Research Clinic, Inc.
  • Texas
    • Bellaire, Texas, United States, 77401
      • Recruiting
      • Rheumatology Care Center, PLLC
    • El Paso, Texas, United States, 79902
      • Recruiting
      • Texas Arthritis Center
    • Houston, Texas, United States, 77090
      • Recruiting
      • Northwest Houston Arthritis
    • Houston, Texas, United States, 77024
      • Recruiting
      • Novel Research, LLC.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Main Inclusion Criteria:

• Classification of systemic lupus erythematosus (SLE) made according to the 2019 European Alliance of Associations for Rheumatology / American College of Rheumatology (EULAR/ACR) criteria.
• Renal biopsy within 6 months prior to Screening visit indicating Class III or IV active glomerulonephritis with or without co-existing Class V, OR pure Class V membranous LN. If no biopsy was performed within 6 months of Screening, a biopsy will be performed during the Screening period, after all other inclusion/exclusion criteria are verified.
• Active renal disease defined as urine protein/creatinine ratio ≥ 1 mg/mg, assessed on a 24h urine collection.

• eGFR ≥ 15 mL/min/1.73 m^2. Enrollment of participants with eGFR between ≥ 15 and < 30 mL/min/1.73 m^2 requires:

  • a renal biopsy during the screening period showing sclerosis in ≤ 50% of glomeruli,
  • activity index ≥ 2, and chronicity index < 4, on the National Institutes for Health 2018 activity and chronicity indices. These indices must be assessed on the kidney biopsy dated less than 6 months prior to Screening and confirmed by a nephropathologist.

• Initiation of the induction therapy with the mandatory following background therapy:

  1. Mycophenolate mofetil 1-3 g/day orally or mycophenolate sodium 720-2160 mg/day orally at Randomization. This treatment can be in place before Screening or started at Screening.
  2. Corticosteroids: 1-3 intravenous (i.v.) pulses of methylprednisolone at 250 to 1000 mg/pulse/day (maximum cumulative 3000 mg) followed by oral prednisone (or equivalent) at 0.5 mg/kg/day with a cap at 40 mg/day. Pulses can be administered during screening and up to 2 weeks prior to screening. Participants who cannot take the pulse i.v. corticosteroid therapy should directly start on 0.8-1.0 mg/kg/day (max 80 mg/day) oral prednisone (or equivalent), within the same window as i.v. pulses.

Note: If treatment with an antimalarial or belimumab is taken, it must be initiated at least 4 weeks prior to Screening and must be at stable dose during these 28 days prior to Randomization and continued at a stable dose until End-of-Treatment. Participants on azathioprine must be switched to mycophenolate mofetil or mycophenolate sodium prior to Randomization.

• Participants of childbearing potential must agree to:

  • Use a highly effective method of contraception from the Screening visit up to at least 24 weeks after discontinuation of trial intervention.
  • Undertake monthly urine pregnancy tests during the trial and up to at least 24 weeks after discontinuation of trial intervention.

Main Exclusion Criteria:

• Severe active central nervous system lupus
• History of, or current renal diseases (other than LN) that, in the opinion of the investigator, could interfere with the LN assessment and confound the disease activity assessment (e.g., diabetic nephropathy), or require dialysis, transplantation or end-stage renal disease.
• History or presence of Mobitz type II or third-degree atrioventricular block, sick sinus syndrome, symptomatic bradycardia, or syncope associated with cardiac disorders.
• Participants who experienced myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, vascular thrombosis, decompensated heart failure requiring hospitalization, or heart failure defined by the New York Heart Association Class III/IV within 6 months prior to Screening.
• Resting heart rate < 50 bpm as measured by the 12-lead electrocardiogram (ECG) at Screening or at Randomization.
• Diagnosis of active or latent tuberculosis at Screening or within 6 months prior to Screening
• Negative antibody test for varicella-zoster virus
• Positive results for serological markers for hepatitis A, B, C and E indicating acute or chronic infection
• Participants with a positive human immunodeficiency virus (HIV) test or who have any other congenital or acquired immunodeficiency

• Presence of any of the following abnormalities, detected during the ophthalmological evaluation and/or by optical coherence tomography, as evaluated by the site ophthalmologist, during Screening:

  • Macular edema of any cause: diabetic, cystoid, tractional.
  • Foveal degeneration: macular hole, macular pseudohole, hereditary or degenerative maculopathies.
  • Active uveitis, papilledema.
  • Retinal neovascularization of any cause and in any location.

• Significant hematology abnormality at Screening:

  • Hemoglobin < 7 g/dL;
  • Lymphocyte count < 500 /μL (0.5 × 10^9/L);
  • White blood cell count < 1500/μL (1.5 × 10^9/L) or
  • Platelets < 25,000/μL (25 × 10^9/L)
• Treatment with the following medications within 5 half-lives of the medication prior to Randomization: Cyclosporine, voclosporin, tacrolimus, sirolimus, cyclophosphamide.

• Treatment with the following medications within 90 days prior to Randomization:

  • Leflunomide.
  • i.v. immunoglobulins.
  • Methotrexate.
  • Tyrosine kinase inhibitors.
• Treatment with anifrolumab within 6 months prior to Randomization.
• Treatment with biological immunosuppressive agents, (e.g., anti-tumor necrosis factor [anti-TNF], anti-interleukin-1 [anti-IL1], anti-IL6 therapies) within 90 days prior to Randomization.
• Treatment with B cell-depleting biological agents (e.g., rituximab, obinutuzumab or ocrelizumab) within 12 months prior to Randomization.

• Treatment with any of the following medications any time prior to Screening:

  • Alemtuzumab.
  • Sphingosine-1-phosphate receptor modulators (e.g., fingolimod).
  • Participants previously randomized to cenerimod or placebo in any trial involving cenerimod.
• Pregnancy confirmed via a serum pregnancy test at the Screening visit or a urine/serum pregnancy test at the Randomization visit or planning to become pregnant, or lactating participant.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cenerimod 4 mg; Participants will receive cenerimod once daily in addition to background lupus nephritis (LN) therapy.	Drug: Cenerimod; Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.; Other Names: ACT-334441
Placebo Comparator: Matching placebo; Participants will receive matching placebo once daily in addition to background LN therapy.	Drug: Placebo; Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete renal response (CRR)	CRR at Week 76, defined as (both must be met): Urine protein to creatinine ratio (UPCR) ≤ 0.5 mg/mg AND; No decrease from baseline of ≥ 20% in estimated glomerular filtration rate (eGFR)	At Week 76

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CRR while maintaining a low dose of corticosteroids	CRR at Week 76 with oral daily dose of 5 mg/day prednisone equivalent or less from Week 24 onwards	At Week 76
Sustained CRR	Sustained CRR at Week 76. Sustained CRR is defined as meeting CRR criteria for two consecutive visits (i.e., 3 months apart) and confirmed at Week 76 visit. The second consecutive visit can be the Week 76 visit to qualify as sustained CRR.	Up to Week 76

Collaborators and Investigators

• Sponsor: Viatris Innovation GmbH
• Investigators: Study Director: Clinical Trials, Viatris Innovation GmbH

Study record dates

Study Major Dates

• Study Start (Actual): February 9, 2026
• Primary Completion (Estimated): August 1, 2029
• Study Completion (Estimated): February 1, 2030

Study Registration Dates

• First Submitted: September 23, 2025
• First Submitted That Met QC Criteria: September 23, 2025
• First Posted (Actual): October 1, 2025

Study Record Updates

• Last Update Posted (Actual): May 22, 2026
• Last Update Submitted That Met QC Criteria: May 19, 2026
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Glomerulonephritis; Nephritis; Skin and Connective Tissue Diseases; Lupus Erythematosus, Systemic; Lupus Nephritis; cenerimod
• Other Study ID Numbers: ID-064B301

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No